A REVIEW ON HPLC METHOD DEVELOPMENT AND VALIDATION STUDIES OF COMBINED DOSAGE FORM OF IVACAFTOR AND TEZACAFTOR

SANDHYA MADHURI MADDALA; JAHNAVI PARVATHI KOLA; SARIKA SUPRIYA ILLA

doi:10.22159/ijpps.2025v17i10.55557

Authors

SANDHYA MADHURI MADDALA Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences and Technologies, Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh-533003, India https://orcid.org/0000-0001-5794-2670
JAHNAVI PARVATHI KOLA Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences and Technologies, Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh-533003, India https://orcid.org/0009-0000-6701-3488
SARIKA SUPRIYA ILLA Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences and Technologies, Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh-533003, India https://orcid.org/0009-0002-9209-8676

DOI:

https://doi.org/10.22159/ijpps.2025v17i10.55557

Keywords:

Analytical method development, HPLC, Ivacaftor, Tezacaftor, Cystic fibrosis

Abstract

The establishment of reliable and precise analytical methodologies plays a critical role in pharmaceutical research, manufacturing processes, and quality assurance. These methods are essential not only for identifying active pharmaceutical ingredients (APIs) but also for detecting contaminants and unintended chemical entities that may enter drug formulations during the production process. Before an analytical method can be implemented in commercial pharmaceutical manufacturing, it must be thoroughly validated by the International Council for Harmonisation (ICH) guidelines to confirm its accuracy, precision, specificity, and reliability. Cystic fibrosis (CF) is a genetic disorder affecting the lungs, digestive, and reproductive systems, caused by mutations in the CFTR gene that result in the accumulation of thick, sticky mucus leading to respiratory and digestive complications. A key therapeutic strategy for CF involves combination therapy using Tezacaftor (TZR) and Ivacaftor (IVR), two drugs that target the underlying genetic defect and improve the function of the CFTR protein. This article reviews the development and validation of analytical and bioanalytical methods for Tezacaftor and Ivacaftor, using Ultra and High-Performance Liquid Chromatography (UPLC/HPLC), and advanced techniques like LC-Tandem Mass Spectrometry (LC-MS/MS). The review outlines key steps in method development, including optimisation of chromatographic parameters and validation processes necessary to ensure that the drugs meet the required standards of purity, potency, and quality. Emphasis is placed on the importance of reliable HPLC and bioanalytical methods in supporting the production of these essential CF therapies while adhering to stringent regulatory requirements.

Downloads

Download data is not yet available.

References

1. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701-26. doi: 10.1146/annurev.biochem.75.103004.142532, PMID 18304008.

2. O Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5, PMID 19403164.

3. Ramsey BW, Davies J, Mc Elvaney NG, Tullis E, Bell SC, Drevinek P. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-72. doi: 10.1056/NEJMoa1105185, PMID 22047557.

4. Taylor Cousar JL, Munck A, McKone EF, Van Der Ent CK, Moeller A, Simard C. Tezacaftor ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377(21):2013-23. doi: 10.1056/NEJMoa1709846, PMID 29099344.

5. Donakonda M, Indrakanti S, Pasala PK, Desari M, Kammari S. A rapid RP-HPLC method for the simultaneous estimation of ivacaftor and tezacaftor and in silico study of their metabolitic products. Futur J Pharm Sci. 2021;7(1):2-14. doi: 10.1186/s43094-021-00254-y.

6. ICH Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2(R1). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2005.

7. Kiranjyothi R, Balakrishnan M, Chandrasekhar KB. Method development and validation for the stability indicating simultaneous estimation of Tezacaftor and ivacaftor in bulk and its dosage forms. Future J Pharm Sci; 2018.

8. Maneka SL, Saravanakumar RT, Anjana CH, Anjana CHK VLSN. Development and validation of stability indicating RP UPLC method for the simultaneous estimation of tezacaftor and ivacaftor in formulations. Int J Pharm Pharm Sci. 2020;12(9):63-70. doi: 10.22159/ijpps.2020v12i9.38412.

9. Vonk SE, Van Der Meer Vos M, Bos LD, Neerincx AH, Majoor CJ, Maitland Van Der Zee AH. Quantitative method for the analysis of ivacaftor hydroxymethyl ivacaftor ivacaftor carboxylate lumacaftor and tezacaftor in plasma and sputum using liquid chromatography with tandem mass spectrometry and its clinical applicability. Ther Drug Monit. 2021;43(4):555-63. doi: 10.1097/FTD.0000000000000829, PMID 33165217.

10. Zheng Y, Rouillon S, Khemakhem M, Balakirouchenane D, Lui G, Abdalla S. A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor elexacaftor tezacaftor hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma. J Pharm Biomed Anal. 2024 Sep 15;248:116322. doi: 10.1016/j.jpba.2024.116322, PMID 38964167.

11. Habler K, Kalla AS, Rychlik M, Bruegel M, Teupser D, Nahrig S. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor lumacaftor, tezacaftor, elexacaftor and their major metabolites in human serum. Clin Chem Lab Med. 2022 Jan 26;60(1):82-91. doi: 10.1515/cclm-2021-0724, PMID 34668357.

12. Drug Bank. Ivacaftor. Available from: www.https://go.drugbank.com/drugs/db08820.

13. Drugbank T. Drug Bank. Available from: https://gocom/drugs/db11712. [Last accessed on 12 Apr 2025].

14. Rama Ayyappa M, Raveendra Babu GR, Sushama C, Sowjanya M, Lakshmana Murthy G. Development and validation of a novel stability indicating RP-HPLC method for the simultaneous estimation of tezacaftor and ivacaftor in combined tablet dosage form. J Chromatogr Sci. 2020 Jun;58(6):456-62. doi: 10.1093/chromsci/58.6.456, PMID 32470108.

15. Devikasubramaniyan G, Rajendran R, Anandhakumar C. A novel RP HPLC method for the estimation of ivacaftor and tezacaftor in bulk and pharmaceutical dosage formulations. Int J Pharm Anal Res. 2023 Jan-Mar;12(1):9-15. doi: 10.61096/ijpar.v12.iss1.2023.9-15.

16. Laxmi Prasanna M, Bakshi A, Bhagavan Raju M. New RP HPLC method development and validation for simultaneous estimation and forced degradation studies of ivacaftor and tezacaftor in solid dosage form. World J Pharm Res. 2019 Dec;8(13):913-22. doi: 10.20959/wjpr201913 15977.

17. Singh N, Bansal P, Maithani M, Chauhan Y. Development and validation of a novel stability indicating RP-HPLC method for simultaneous determination of tezacaftor and ivacaftor in fixed dose combination. J Chromatogr Sci. 2020 Apr;58(4):346-54. doi: 10.1093/chromsci/bmz120, PMID 31953544.

18. Balaswami B, Venkata Ramana P. A new stability-indicating RP UPLC method development and validation for the simultaneous estimation of ivacaftor and tezacaftor in the pharmaceutical dosage form. Int J Pharm Biol Sci. 2019;9(4):1158-66. doi: 10.21276/ijpbs.2019.9.3.143.

19. Shyamala DA. A novel stability-indicating UPLC method for the estimation of tezacaftor and ivacaftor in tablet dosage form. Int J Pharm Sci Res. 2019 Nov;10(11):4968-73. doi: 10.13040/IJPSR.0975-8232.10(11).4968-73.

20. Venkata MS, Rao AL, Carey MW. Simultaneous estimation of ivacaftor and tezacaftor in rat plasma by liquid chromatography coupled with tandem mass-spectrometry: application to pharmacokinetic studies. Thai J Pharm Sci. 2021;45(6):451-60. doi: 10.56808/3027-7922.2526.

21. Sutar SV, Yeligar VC, Patil SS. A review: stability indicating forced degradation studies. Res J Pharm Technol. 2019;12(2):885-90. doi: 10.5958/0974-360X.2019.00152.5.

22. Indira Priyadarshini G, Mounika V, Anjani G, Sowmya B. Stability indicating RP HPLC method development and validation for the simultaneous estimation of tezacaftor and ivacaftor in bulk and pharmaceutical dosage form. Asian J Pharm Anal. 2020;10(1):19-26. doi: 10.5958/2231 5675.2020.00005.

23. Marakatham S, Shanmugapandiyan P. Stability indicating bioanalytical validation of elexacaftor ivacaftor and tezacaftor using HPLC in human plasma. Res J Pharm Technol. 2023;16(8):3780-6. doi: 10.52711/0974-360X.2023.00624.

24. Alle S, Ubbani R, Gangadi JR, Tomar S, Kokkula PK. Ensuring stability and accuracy: bioanalytical validation of elexacaftor ivacaftor and tezacaftor in human plasma by HPLC analysis. J Chem Pharm Sci. 2024;17(1):18-27.

25. Zehra F, Begum KA, Ramakrishna D. Method development and validation of simultaneous estimation of tezacaftor and ivacaftor in API by RP-HPLC. Int J Pharm Ind Res. 2021;11(2):18-27.

26. Pavani K, Sravanasree B, Vineela M. A new RP-HPLC method for the determination of tezacaftor and ivacaftor in bulk form and marketed pharmaceutical dosage form. Indo Am J Pharm Sci. 2023 Jul;10(7):122-34. doi: 10.5281/zenodo.8206048.

27. Patel D, Patel J, Patel N. Development and validation of a stability indicating RP-HPLC method for simultaneous estimation of paracetamol and diclofenac potassium in bulk and combined dosage form. Int J Curr Pharm Rev Res. 2019;10(3):1-7.

28. Kumar V, Sharma V, Singh S. Simultaneous estimation of metformin hydrochloride and sitagliptin phosphate monohydrate by UV spectrophotometric method in tablet dosage form. Int J Appl Pharm. 2017;9(5):29-34. doi: 10.22159/ijap.2017v9i5.20578.

29. Choudhary D, Kaur N, Singh S. Simultaneous spectrophotometric estimation of amlodipine besylate and valsartan in pharmaceutical dosage form. Asian J Pharm Clin Res. 2018;11(7):1-5. doi: 10.22159/ajpcr.2018.v11i7.25051.

30. Singh P, Singh K, Singh S. Development and validation of simultaneous estimation of rabeprazole sodium and domperidone by UV spectrophotometric method in combined dosage form. Int J Curr Pharm Rev Res. 2018;9(4):45-51.

31. Kumar A, Sharma S, Saini S. RP-HPLC method development and validation for simultaneous estimation of paracetamol and aceclofenac in tablet dosage form. Asian J Pharm Clin Res. 2019;12(10):233-7. doi: 10.22159/ajpcr.2019.v12i10.33038.